Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its Q2 2021 financial results on August 12, 2021, following the market close. The management will host a conference call and webcast at 4:30 p.m. ET to discuss results and recent corporate updates. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue at a fraction of MRI costs, particularly for assessing liver conditions like NAFLD and NASH. The technology is compatible with numerous existing ultrasound systems.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. This event includes 1-on-1 virtual investor meetings, allowing investors to connect with the management team. ENDRA is a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that visualizes tissue at a fraction of MRI costs. TAEUS® targets chronic liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), affecting over one billion people globally.
ENDRA Life Sciences (NASDAQ:NDRA) has expanded its patent portfolio with three newly issued patents from the USPTO related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include methods for estimating liver fat content, determining material parameters, and monitoring temperature during thermal ablation. This growth in intellectual property, now totaling 86 assets, is aimed at enhancing the commercial application of TAEUS®, which targets significant medical challenges like Non-Alcoholic Fatty Liver Disease. The company emphasizes protecting its innovations in key global markets.
ENDRA Life Sciences (NASDAQ:NDRA) has appointed Irina Pestrikova as the new Senior Director of Finance and Principal Financial Officer, effective June 18, 2021. She will take over the responsibilities previously held by David Wells, who is departing to pursue another opportunity. Pestrikova has been with ENDRA since 2014, contributing to its financial planning and accounting functions. Wells will assist in the transition until September 2021.
This leadership change comes as ENDRA continues to innovate with its Thermo Acoustic Enhanced UltraSound (TAEUS) technology for liver and other clinical applications.
ENDRA Life Sciences (NASDAQ:NDRA) is set to be added to the Russell Microcap Index, effective June 28, 2021, following a preliminary announcement on June 4. The CEO, Francois Michelon, expressed enthusiasm for this milestone, highlighting its potential to enhance the company's visibility in the investment community. Membership in this index serves as a benchmark for smaller growth stocks and facilitates automatic inclusion in various growth and value style indexes, benefiting approximately $10.6 trillion in asset benchmarks.
ENDRA Life Sciences (NASDAQ:NDRA) reported its Q1 2021 financial results, revealing a net loss of $2.3 million ($0.06 per share), an improvement from a loss of $3.3 million ($0.29 per share) in Q1 2020. Operating expenses decreased to $2.6 million from $3.1 million year-over-year. The company secured a total of $12.6 million through warrant exercises and its ATM facility. Significant advancements include partnerships with Hepion Pharmaceuticals and Inselspital University Hospital for clinical validation of the TAEUS system, aimed at assessing liver conditions. Cash reserves stood at $16.8 million as of March 31, 2021.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced it will report its first quarter 2021 financial results on May 17, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent corporate developments. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®), a cost-effective ultrasound technology aimed at assessing liver conditions affecting over 1 billion individuals worldwide. More information can be found on their website.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced the issuance of two U.S. patents related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include the '624 patent, which enhances TAEUS probe functionality, and the '163 patent, which protects the design of its thermoacoustic imaging probe. Both patents aim to improve diagnostic capabilities for conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), affecting over 1 billion globally. ENDRA also highlighted its growing intellectual property portfolio, now at 85 assets, and ongoing clinical partnerships, especially with GE Healthcare.
ENDRA Life Sciences (NASDAQ:NDRA) will present its Thermo Acoustic Enhanced Ultrasound (TAEUS™) technology at the AIUM Annual Integrative Ultrasound Meeting on April 14, 2021, at 11:45 am ET. The presentation, led by CTO Michael Thornton, will overview TAEUS and its application in measuring liver fat, targeting conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) affecting over one billion people worldwide. ENDRA will also showcase its TAEUS liver system in a virtual booth from April 11 to April 25.
ENDRA Life Sciences (NASDAQ:NDRA) reported its financial results for Q4 and FY 2020, with a net loss of $2.3 million ($0.10/share) in Q4, down from $4.8 million in 2019. Total operating expenses decreased to $2.3 million from $3.1 million in Q4 2019. For the full year, net loss was $11.7 million ($0.63/share), improved from $13.3 million in 2019. The company secured partnerships and clinical studies in Europe, strengthened its intellectual property, and raised $18.5 million through stock sales. A call to discuss results was scheduled for 4:30 PM ET today.